Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Sep;95(38):e4967.
doi: 10.1097/MD.0000000000004967.

Ocular manifestation in myeloid/NK cell precursor acute leukemia: a case report. Diagnosed by flow cytometry and PCR from aqueous humor

Affiliations
Case Reports

Ocular manifestation in myeloid/NK cell precursor acute leukemia: a case report. Diagnosed by flow cytometry and PCR from aqueous humor

Sayaka Akaike et al. Medicine (Baltimore). 2016 Sep.

Abstract

Background: Myeloid/NK cell precursor acute leukemia (MNKL) is a rare type of leukemia, and ocular complications have not previously been reported. We now report a patient with MNKL who developed intraocular infiltrates during follow-up.

Methods and results: A 13-year-old boy diagnosed with MNKL developed left eye pain 3 months after starting treatment. Examination of the left eye revealed a visual acuity of counting fingers at 20 cm, ciliary hyperemia, small corneal keratic precipitates, hypopyon, grade 4 vitreous opacities, and an obscured fundus. The differential diagnosis was between an opportunistic infection associated with immunodeficiency and an intraocular leukemic cell infiltrate. Therefore, a sample of aqueous humor was aspirated. Multiplex PCR/broad-range PCR of the aqueous humor was below detection limits for viruses, bacteria, and fungi. Flow cytometry (FCM) detected NK-related CD56-positive cells, thus leading to a diagnosis of ocular infiltrates due to MNKL. With treatment of the ocular infiltrates by consolidation systemic chemotherapy including intrathecal methotrexate (MTX), there was clearing of the vitreous opacities; and optic disc swelling, retinal hemorrhages, exudates, and protuberant lesions were now seen. With the addition of local radiation therapy to the eye, there was a dramatic treatment response, with regression of the optic disc findings and retinal lesions, and an improved visual acuity of 1.5.

Conclusion: We encountered the first case of MNKL in which ocular infiltrates developed during follow-up. Multiplex PCR and FCM of the aqueous humor were useful in rapidly distinguishing leukemic cell infiltrates from an opportunistic infection. This case highlights the usefulness of intrathecal MTX and local radiotherapy in treating ocular infiltrates in patients with MNKL.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
(A) Slit lamp examination at initial evaluation. There was ciliary injection and a hypopyon in the left eye (white arrow). (B) Funduscopy at initial evaluation. The fundus was obscured due to grade 4 vitreous opacities.
Figure 2
Figure 2
Flow cytometry of the aqueous humor. CD56-positive natural killer (NK) cells were detected in the aqueous humor. (A) Gating of infiltrating cells in the aqueous humor. (B) Confirmation of CD56-positive cell infiltrates (upper left panel).
Figure 3
Figure 3
Cranial computed tomography (CT) and magnetic resonance imaging (MRI) findings. No infiltrates of the orbit or optic nerve were present.
Figure 4
Figure 4
(A) Fundus after systemic chemotherapy with intrathecal methotrexate (MTX). Corrected visual acuity was 0.6. Examination of the fundus, which could now be visualized, showed retinal hemorrhages, exudates, protuberant lesions in the retinal periphery (white arrow), and swelling of the optic disc. (B) After radiation therapy (1.5 Gy × 17). Corrected visual acuity was 1.0. At 4 months after starting treatment, the optic disc swelling improved, the protuberant lesions in the retina disappeared, and only a few retinal exudates remained (white arrow).

References

    1. Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 1997; 90:2417–2428. - PubMed
    1. Morimoto M, Kondoh K, Keino D, et al. A child with myeloid/natural killer cell precursor acute leukemia treated successfully with acute myeloid leukemia-oriented chemotherapy incorporating L-asparaginase. Leuk Res 2010; 34:1677–1679. - PubMed
    1. Handa H, Motohashi S, Isozumi K, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside. Acta Haematol 2002; 108:47–52. - PubMed
    1. Gordon KB, Rugo HS, Duncan JL, et al. Ocular manifestations of leukemia: leukemic infiltration versus infectious process. Ophthalmology 2001; 108:2293–2300. - PubMed
    1. Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role. Eye (Lond) 2004; 18:663–672. - PubMed

Publication types

MeSH terms